← Back to all signals
RESEARCH PAPER ANALYSIS

Sleep depth and cognitive function in Parkinson's disease: An analysis using the Odd's Ratio Product (ORP).

This polysomnography study shows that ORP measures of sleep depth—particularly the overnight change in ORP (ORPdiff)—differ between PD and OSA groups and that smaller ORPdiff (less restorative sleep) is associated with worse cognition and greater non-motor symptoms in Parkinson's disease.

PMID41962180
JournalSleep medicine
Publication Date2026-04-08
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This polysomnography study shows that ORP measures of sleep depth—particularly the overnight change in ORP (ORPdiff)—differ between PD and OSA groups and that smaller ORPdiff (less restorative sleep) is associated with worse cognition and greater non-motor symptoms in Parkinson's disease.

WHY IT MATTERS

Research significance

Suggests ORP-derived sleep-depth metrics could serve as objective biomarkers of cognitive vulnerability and non-motor burden in PD and highlights sleep restoration as a potentially modifiable target for therapeutic strategies, although causal mechanisms and intervention data are lacking.

ABSTRACT

Source abstract

BACKGROUND: Obstructive sleep apnea (OSA) is linked to cognitive dysfunction in Parkinson's disease (PD) and the general population. Sleep depth, measured by Odds Ratio Product (ORP), may offer novel insights into this relationship. We characterized sleep depth across PD and OSA groups and examined associations with cognitive function. METHODS: We analyzed polysomnography and Montreal Cognitive Assessment (MoCA) data from individuals with PD (n = 217) and controls (n = 633). Participants were grouped as: PD+OSA+, PD+OSA-, PD-OSA+, PD-OSA-. ORP metrics included: ORPTRT (average across total recording time), ORPN2, ORPNREM and ORPREM (during sleep stages), ORP-9 (post-arousal), ORPdiff (difference beginning to end of sleep), ORPWAKE (during wake epochs), and ORPicc (interhemispheric coherence). Linear and LASSO regression assessed associations with MoCA. Exploratory analyses examined associations with PD symptoms. RESULTS: ORPTRT was higher in PD groups and in PD-OSA+ vs. PD-OSA-. ORPN2, ORPREM, and ORP-9 were lowest in PD-OSA-. ORPdiff was highest in PD-OSA- and lowest in PD+OSA+. ORPREM, ORPWAKE, and ORPdiff were associated with MoCA in the whole sample. Subgroup analyses identified an association between ORPdiff and MoCA in PD only, with a significant interaction between ORPdiff and PD. ORPdiff was also inversely associated with PD non-motor symptoms. CONCLUSION: Both PD and OSA affect sleep depth, with PD exerting a greater impact. Specific sleep depth measures are associated with cognitive function. Non-restorative sleep (lower ORP difference across the night) relates to cognitive function in PD only, and to greater non-motor PD symptoms. ORP may help distinguish PD- from OSA-related sleep changes, and impact on cognitive vulnerability.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic